SOURCE: Medistem Laboratories, Inc.

January 04, 2007 08:05 ET

Medistem Laboratories Appoints Thomas Ichim to Be Chief of Scientific Development

Accomplished Industry Leader to Head Medistem's Scientific Development Programs in Adult Stem Cell Technologies

SCOTTSDALE, AZ -- (MARKET WIRE) -- January 4, 2007 -- Medistem Laboratories, Inc. (OTCBB: MDSM), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, announced today that Thomas Ichim, a veteran of the cell therapy industry with expertise in development and implementation of novel therapeutics in the area of biologics, has joined the Company as its Chief of Scientific Development.

"We're very excited to have a seasoned scientific mind like Thomas join our management team at Medistem Laboratories," said Neil Riordan, Ph.D., CEO of Medistem. "Tom has been involved at the highest levels of translational research ranging from basic scientific discoveries all the way to regulatory approval. His depth and breadth of knowledge in the areas of stem cell biology and immunology are going to be of significant value to the company going forward."

"As we continue to grow and expand we feel it is crucial that Medistem's affiliated operations are clearly aligned with the highest standards of scientific and clinical practice. Based on Tom's rich background we think he will have a significant impact in these areas and look forward to his expertise and guidance," said Riordan.

Ichim has served a variety of instrumental roles for companies operating in the area of biologics. He obtained numerous regulatory approvals for companies such as MarrowTech Pharma, and worked as a Program Director for the global CRO bioRASI, under which he led efforts to develop, clinically assess, and approve various stem cell and cellular therapies. Ichim has also founded two companies, ToleroTech Inc. and MedVax Pharma Corp., which are developing proprietary technologies in the areas of RNA interference and cancer vaccines, respectively. Ichim is an accomplished scientist with 15 scientific papers published in areas ranging from immunological tolerance, to cancer therapy, to autoimmunity. Additionally Ichim has numerous patents filed and issued covering diverse topics.

"The stem cell space is an extremely exciting area to be in and I believe Medistem's technology and business model are truly unique in this industry," Ichim said. "It is very, very rare to see a company that synergistically combines cutting edge technologies with medical realities on a practical level. The combination of scientific, medical and intellectual property expertise assembled at Medistem position this company to be an industry leader, and I am excited to be part of this."

About Medistem Laboratories, Inc.

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company intends to create these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. Initial development and treatment focus will use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for advanced treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases, primarily for the international marketplace. Additional applications ultimately will be targeted to the treatment of neurological disorders such as Parkinson's, Alzheimer's and certain types of cancer. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.

Contact Information